Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

Orphan Drug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum

ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent developments in its program for ENMD-2076, an Aurora A/angiogenic kinase inhibitor. These developments include the presentation of initial results for a Phase 1 study in patients with refractory solid tumors as well as preclinical data showing significant potential for the use of ENMD-2076 in combination with platinum-based chemotherapy in breast cancer. In addition, EntreMed has received an Orphan Drug Designation from the FDA for the treatment of multiple myeloma using ENMD-2076. To further enhance its clinical development efforts for the drug candidate, a No Objection Letter was received by EntreMed from Health Canada permitting ENMD-2076 to be used in clinical trials within Canada. Data for the Phase 1 study in solid tumors, which is being conducted at the University of Colorado Cancer Center and the Dana-Farber Cancer Institute, were presented by Jennifer Diamond, M.D., during an oral presentation at the 11th International Symposium on Anti-Angiogenic Agents held last week in San Diego, California. Dr. Diamond is a Hematology/Oncology Fellow, working in the Developmental Therapeutics Program of the University of Colorado.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Results from the ongoing Phase 1 study in patients with refractory solid tumors demonstrated that ENMD-2076 administered orally in 28-day cycles was well tolerated. Data show preliminary evidence of antitumor activity as determ
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...Nov. 27 Booth - 3646/Sou...VAR ), a premier supplier of X-ray tubes and flat ...ll range of detectors at the RSNA Annual Meeting i...9. Varian will also be exhibiting X-ray tube tech...zed cancer treatment technologies. ,, Varian,s...
(Date:11/25/2009)...f., Nov. 25 Praxis Electronic Medi...merican Academy of Family Physicians, (AAFP) Famil...tion Survey for improving medical quality, health ...for new ARRA Stimulus legislation. Praxis also ran...sitive effect in determining their salary. Finally...
(Date:11/25/2009)...ov. 25 Pharmasset, Inc. ...company committed to discovering, developing and c...ns, reported financial results for the fiscal year...harmasset held $58.4 million in cash, cash equival...Update and 2009 Highlights ,, RG7128 ,, ...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Radiation Rescue 3A 4 Steps to Safeguard Your Family from the Other Inconvenient Truth The Health Hazards of Wireless Technology 49460 1Radiation Rescue 3A 4 Steps to Safeguard Your Family from the Other Inconvenient Truth The Health Hazards of Wireless Technology 49460 2Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Piper Jaffray Conference 12706 1NeuroTherm Completes Acquisition of the Micron Epidural Catheter 49458 1NeuroTherm Completes Acquisition of the Micron Epidural Catheter 49458 2
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 ...ed that Blair Lambert, CFO/COO, will present at th...held at the May Fair Hotel in London, England, on ..., To listen to a live broadcast of The Gymboree ...se log on to www.gymboree.com, click on "Our Compa...
(Date:11/27/2009)..., NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewswir...rofessional cycling team dedicated to ethical spor... champions, announced today that it will become Te...ions Optical as a new sponsor of the team. Transit...f adaptive eyewear, offering the most advanced pho...
(Date:11/27/2009)... XenaCare Holdings has announced t...tis Foundation, one of the largest nonprofit organ...c health education. , Del...e Holdings, Inc. (OTCBB: XCHO), a company speciali...onsumer healthcare products, has announced today t...
(Date:11/27/2009)...ates to bring unprecedented medical, economic burd...(HealthDay News) -- The number of people with diab...er the next 25 years, a new study predicts. , T...llion people with the disease, up from 23.7 millio...ing people with diabetes will triple, the study al...
(Date:11/27/2009)... Voyant Health™ announced to...has licensed its TraumaCad Enterprise orthopedic t...ow solution. , (PRWEB) No...today that Spectrum Health (Grand Rapids, Michigan... templating solution and its TraumaCad Extend work...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...ey, California have come out with a tremendous tec... information held in store in the human genome. Th...dowing". An analysis through this technique helps ... patterns' that identify these primate families un...
...t cancer are put off just with the news and then f...akes 6 weeks, disrupts their world completely. How...asier and less disruptive way of treating these ca...doctors will now be able to deliver the same cance...
...attempt to find out how various eating styles were...mpared the blood pressures of meat eaters, fish ea...ch were published in Public Health Nutrition, show...blood pressure and others with normal blood pressu...
...are one of the most exquisite pieces of engineerin...the eyes become vulnerable to a debilitating degen...eaking down, which ultimately might lead to blindn...ough nutrients that work as antioxidants. The...
... sharp rise in the use of alternative treatments a...entifically document the effects of hundreds of he...now, there was// no easy access to current, compre...ill provide up-to-date information on the safety a...
...y of us, though very annoying, are just a harmless...for many sick people who have weakened immune syst...ttacks launched against their blood vessels and in...ering them ineffective for treatment of several se...
Other Medicine News:Health News:Primates reveal a new dimension to human genome, 2Health News:Cut meat to cut blood pressure 2Health News:New insights into herbal supplements 2Health News:Fight against Fungus - A new ray of hope 2
RESTASIS®
LADARWave® Aberrometer
ZYMAR™ 2.5 mL
REFRESH TEARS®
Medicine Products: